Early deal gets bigger worm

It might look like Metabasis Therapeutics Inc. would have been better off keeping its pradefovir hepatitis B compound longer and reaping the benefits of licensing it out at a later stage, but the company says it had good strategic reasons for early out-licensing and doesn't mind having Valeant Pharmaceuticals International as a middleman between itself and new

Read the full 570 word article

How to gain access

Continue reading with a
two-week free trial.